from seed to market.
The Trendlines Group invests in innovations in agrifood technologies and medtech, leveraging our experience, network, and resources to go from seed to market.
Vensica has developed minimally invasive solutions in urology, unlocking the unique properties of therapeutic ultrasound to deliver neurotoxins.
Vensica’s journey from our establishment in 2014, through to our strategic partnership with Merz and the latest investment round, took many twists and turns. Trendlines was there for us at each stage.
Avner Geva, CEO Vensica Therapeutics
Strategic license and collaboration agreement with Merz Therapeutics
Full development of a needle-less delivery system utilizing the power of therapeutic ultrasound
$19 million investment round led by Israeli VC IBF
Phytolon revolutionizes the way food colors are produced, bringing natural colors to the next level in terms of ...
The investments of DSM Venturing, Cibus Fund, and Ginkgo Bioworks open the door for broad penetration of our products in the global food industry. We are excited to have new investors who share our vision to create healthy, efficient, and sustainable food systems via biotechnology.
Halim Jubran PhD, Co-founder and CEO of Phytolon
Closed $14.5 million Series A funding round
Signed collaboration with Ginkgo Bioworks
Selected as one of top 30 global start-ups at SLINGSHOT 2019, Singapore, November 2019
4 January 2023
liberDi receives FDA regulatory clearance for its digital dialysis system
Potential to become the standard of care for home peritoneal dialysis
14 December 2022
The Edge and the SGX – 10 in 10 with Trendlines
15 November 2022
Collaborative study by NeuroQuest and AIBL shows specific biomarkers for Alzheimer’s could lead to blood-based screening tool
Misgav Business Park, 17 T’chelet Street M.P. Misgav, 2017400
Blk 77, Ayer Rajah Crescent, #02-21/26 Singapore, 139954